Citations

Showing 10 of 108152 citations.

Abstract 3229: First Time Validation of Point to Point NavX Map Registration to 3D Subject-Specific Computed Tomography (CT)
Kolasa, Mark, Johnson, Susan B., Olson, Eric, Schweitzer, Jeffrey S. , Packer, Douglas L. , Okumura, Yasuo , Schweitzer, Jeffrey

Mayo Clinic

Circulation | July 3, 2021 | Volume: 116 | Issue: suppl_16 | Pages: No page available

10.1161/circ.116.suppl_16.ii_726-c Get It

Background: Current mapping systems use simultaneous displays of overlapping 3D maps and pre-acquired CT images of the LA to “pseudo-register” data sets rather than specifically “register” each point of one mapping data set to the other. The appropriateness of the 2 data set match has not been validated. Since significant surface to surface mismatch errors may occur, this study was undertaken to quanititatively validate NavX map to CT registration and determine its suitability for guiding AF ablation. Methods: Sixty-four slice, multidetector CT scans were acquired in 8 dogs and segmented to establish subject-specific LA/PV volumes for importation into the EnSite mapping system. A detailed multi-surface geometry (NavX map) was collected by navigating a mapping catheter in target LA and PVs. Using a novel developmental registration algorithm the map was registered to LA/PV CT volume. Validation was performed using the registered 3D CT model for the guidance of ablation at the location of multiple implanted radio-opaque markers. Results: A total of 39 radio-opaque markers were implanted before CT including 9 LSPV, 8 RSPV, 7 RIPV, 9 LIPV, 3 roof, and 3 LAA locations. Subsequent registration of individual NavX maps to acquired 3D CT volume was successfully completed in all animals. RF ablations were performed at the predicted 3D registered model locations of the radio-opaque markers using 5 mm tip RF ablation catheter. Resulting mean lesion size was 5.3 x 6.5 mm. The lesions enveloped the point of marker attachment to the myocardium in 31/36 (86%) ablations. The average distance from the center of the RF lesion to the targeted site was 2.5 ± 1.5mm. 47 points were successfully navigated under fluorscopic and ICE guidance. All points were accurately portrayed on the 3D registered model. 3 points in the region of the RSPV floor did have minor offsets on the model due to technically difficult segmentation of the RSPV from the right pulmonary artery. Conclusion: These data demonstrate the feasibility of registering NavX derived geometries to CT data sets accommodating sources of cardiac, respiratory, and translational cycle dependent error. Catheter navigation precisely conducted using the registered model demonstrates accuracy within the range required for RF ablation.
Abstract 3223: Feasibility and Safety of the Integrated 3D Image and Contact Force-Guided Ablation for Atrial Fibrillation with the Hansen Robotic Catheter Sheath System
Henz, Benhur Davi , Johnson, Susa B, Packer, Douglas L. , Okumura, Yasuo , Johnson, Susan B.

Mayo Clinic

Circulation | July 3, 2021 | Volume: 116 | Issue: suppl_16 | Pages: No page available

10.1161/circ.116.suppl_16.ii_725-a Get It

Background: Current technologies to fully “register” surrogate maps onto 3D CT (CartoMerge, NavxMerge) or 3D ICE images (CartoSound) have emerged to guide ablation. The feasibility of navigation with the Hansen Robotic Catheter Sheath System (HRCS) has also been reported. Integrated 3D Image and contact force sensor with this robotic system may allow for feasibility and safety for guiding complex anatomic-based ablation. Methods: Circumferential pulmonary vein (PV) ablation with the robotic system guided by integrated 3D images (CartoMerge, NavxMerge or CartoSound) (n=3), were done and compared to manual manipulation guided by the integrated 3D images (CartoSound) (n=8). Each ablation was performed using contact force ranges of 10 –20 grams (20W, 17 ml/min flow, 30 seconds). Accuracy of PV ablation was assessed by comparing distance from the PV ostia (specific 4 sites) to the ablative points on the 3D image structures, and the corresponding distances of the actual ablative lesions at pathologic exam. Results: Using three integrated 3D image systems, circumferential PV ablation was successfully guided in 6 PVs (3 RSPVs and 3 LSPVs) with the robotic system. During all ablations with contact forces of 10 –20 grams, no impedance rises, pops or type 2 microbubbles were seen. Accuracy of the PV ablation was 0.22±0.84 mm (range 0 –2). The PV rings were 100% circumferential by electroanatomic mapping, yielding an 86±7% (range 80 –98%) uninterrupted circumferential ablative ring around each PV with 1.1 ± 0.4 gaps (3.0 ± 0.9 mm). These resulting parameters were equal to those in the integrated 3D image-based manual navigation (Accuracy: 0.5±0.9 (range 0 –2.5) mm, Gaps:1.3 ± 0.9 ( 2.6 ± 0.9 mm), circumferential lesions 88 ± 10% (range 70 –100). Conclusions: This feasibility study demonstrated successful integrated 3D image and contact force-guided robotic ablation. Contact sensor guided 3D volume construction and real time 3D images accurately replicated atrial and venous anatomy, resulting in successful circumferential ablation.
Abstract 3204: Implications of Preoperative thienopyridine Use in Patients With non-ST Elevation Acute Coronary Syndrome Undergoing Coronary Artery Bypass Surgery: One year Results From the ACUITY Trial
Ebrahimi, Ramin , Feit, Frederick, Manoukian, Steven V., Lincoff, A., Dyke, Cornelius , Moses, Jeffrey, Stone, Gregg W. , Gersh, Bernard J. , Mehran, Roxana , Moses, Jeffrey

Mayo Clinic

Circulation | July 3, 2021 | Volume: 116 | Issue: suppl_16 | Pages: No page available

10.1161/circ.116.suppl_16.ii_720-b Get It

Thienopyridine administration has a class Ia recommendation in patients with non-ST elevation acute coronary syndromes (ACS). Despite this many physicians withhold this treatment until after angiography because of concerns over the minority of patients who may require coronary artery bypass surgery (CABG). We sought to evaluate the one year composite ischemic outcomes (death, myocardial infarction, revascularization) in ACS patients requiring CABG based on thienopyridine exposure and timing of CABG. Methods: In the ACUITY trial, thienopyridine administration and timing was left to investigators’ discretion. In the subset of patients requiring CABG, the one year composite ischemic outcome was compared in those not exposed to thienopyridines (group A), those who received thienopyridine and went to CABG ≤120 hours from the last dose (group B) and those who received thienopyridine and went to CABG >120 hours after the last dose (group C). Major bleeding was defined based on ACUITY definitions. Results: CABG was performed in 1539 (11.1%) patients. There were no significant differences in baseline characteristics among the three groups. Mean time from angiography to CABG, major bleeding, and 1-year composite ischemia are presented in the table below. Conclusions: Based on our analysis of ACS patients undergoing CABG in the ACUITY trial, those who received thienopyridine preoperatively and went to CABG >120 hours from the last dose had improved one year composite ischemic outcomes compared to those not exposed or those who received thienopyridine and went to CABG ≤120 hours after the last dose.
Abstract 3135: Impact Of PCI On The Clinical Burden Of Atherothrombotic Disease. An Analysis From The NHLBI Dynamic Registry
Laskey, Warren K., Selzer, Faith , Mokwe, Evan, King, Spencer B., Cohen, Howard, Tanguay, Jean‐François , Holper, Elizabeth M. , Detre, Katherine, Holmes, David, Slater, James N. , Williams, David James

Mayo Clinic

Circulation | July 3, 2021 | Volume: 116 | Issue: suppl_16 | Pages: No page available

10.1161/circ.116.suppl_16.ii_703-c Get It

Introduction . The addition of percutaneous coronary intervention (PCI) to the treatment options for patients with atherothrombotic (AT) coronary heart disease (CHD) has resulted in considerable debate regarding its overall clinical benefit. Although rates of “hard” clinical endpoints have been used as measures of both clinical outcome and disease burden, a comprehensive, clinically relevant measure of disease burden in the general population of patients undergoing PCI is lacking. Hypothesis . A comprehensive measure of AT clinical burden in patients undergoing PCI can be used to detect the qualitative and quantitative impact of PCI over time. Methods . Four distinct cohorts (Waves) of ~ 2,000 patients each participating in the NHLBI Dynamic Registry beginning in 1997 (Wave 1) and terminating in 2005 (Wave 4) and surviving to hospital discharge comprise the study population (n= 7,750). A composite clincally relevant measure of AT disease burden over the year following PCI was defined as: any death, myocardial infarction (MI), hospitalization for recurrent angina (A) or congestive heart failure (HF), stroke, any repeat PCI or coronary bypass surgery. Cumulative event rates, expressed as the presence of any of the above-cited components by one year, were calculated using Kaplan-Meier statistics. Comparison of rates across Waves was accomplished using Cochran- Mantel-Haenszel method. Results. see Table Exclusion of patients requiring PCI for restenosis did not substantially change the overall AT burden. Conclusion. There was a statistically significant decrease in AT disease burden over the time studied. However, the burden of disease in patients undergoing PCI remains substantial for 25% of patients. This measure of AT burden may be of clinical value in assessing the contribution of PCI to patient outcomes and strongly supports more comprehensive treatment strategies for patients following PCI. Component and composite rates at one year
Abstract 3119: Long-term Safety of Cilostazol in Patients With Peripheral Artery Disease
Hiatt, William R. , Brass, Eric P. , Money, Sam

Mayo Clinic

Circulation | July 3, 2021 | Volume: 116 | Issue: suppl_16 | Pages: No page available

10.1161/circ.116.suppl_16.ii_699-b Get It

Cilostazol, a phosphodiesterase III inhibitor, is indicated to treat the symptoms of claudication in patients with peripheral arterial disease (PAD). At the time of approval the FDA required an additional long-term safety study to evaluate cilostazol’s effect on mortality. Subjects (n=1899) with a clinical diagnosis of PAD and symptoms of claudication were screened for a randomized, double blinded, placebo-controlled safety study of cilostazol. The modified intent-to-treat (mITT) population (n=1435) included all randomized patients who received at least one dose of study medication and includes follow up of more than 30 days after discontinuation of study drug. A total of 717 patients received cilostazol and 718 received placebo. Cilostazol was administered at a primary dose of 100 mg twice daily. Long-term adherence to study medication was poor with over 60% of participants discontinuing therapy by 36 months. Therefore the mortality analysis focused on deaths during the period on-treatment defined as the period during which study drug was taken plus a 30-day post-dosing follow up period. Total patient-years exposure on-treatment for cilostazol was 1046 and on placebo was 1090. On-treatment there were 18 deaths on cilostazol and 19 deaths on placebo for a hazard ratio of 0.99 (95% confidence interval 0.52 to 1.88). Cardiovascular deaths on-treatment occurred in 14 patients on cilostazol and 14 on placebo. In the full mITT population at 36 months, there were 101 deaths, 49 on cilostazol and 52 on placebo with hazard ratio of 0.94 (0.64 –1.39). Thus most deaths occurred more than 30 days after study drug discontinuation. Serious bleeding events affected 18 patients on cilostazol and 22 on placebo in the on-treatment population. Bleeding events were similar in patients also taking aspirin, aspirin plus clopidogrel or anticoagulants over the course of the study. This long-term study demonstrated no safety signal for cilostazol on all cause or cardiovascular mortality. However the study was under-powered to detect a small adverse impact of cilostazol on mortality (hazard ratio upper bound of the 95% confidence interval 1.88 in the on-treatment population). Serious bleeding events appeared not to be increased by cilostazol.
Abstract 3002: Left Ventricular Diameter Predicts Recovery in Acute Cardiomyopathy: Results of the IMAC 2 Trial
Dec, GW, Gorscan, John, Tanabe, Masaki , McNamara, Dennis M. , Starling, Randall C. , Cooper, Leslie T. , Boehmer, John , Liu, Peter Jianrui , Pauly, Daniel F , Kip, Kevin E.

Mayo Clinic

Circulation | July 3, 2021 | Volume: 116 | Issue: suppl_16 | Pages: No page available

10.1161/circ.116.suppl_16.ii_671-c Get It

Introduction : The incidence of spontaneous clinical improvement in acute cardiomyopathy (ACM) patients treated with evidence based medical therapy is unknown. We hypothesized that pts without LV dilatation at presentation would have the greatest potential for recovery of ejection fraction (EF). Methods: A multi-center NHLBI sponsored trial, Intervention in Myocarditis and Acute Cardiomyopathy II (IMAC 2) was designed to study the clinical course of ACM and the mechanisms associated with outcomes. A clinical, echocardiography, and genetics core lab are established. Results: 15 centers have enrolled 215 pts, mean age 45 ± 14 yrs, 34% female, NYHA class I–IV% 18/54/21/7, baseline EF 0.25 ± 0.09. Therapy included 80% beta blockers and 92% ACE or ARB treated. All patients enrolled had symptoms for ≤ 6 mos and were diagnosed with acute, idiopathic cardiomyopathy or myocarditis. Baseline and 6 mo echoes in 140 pts reviewed by the core lab demonstrated increased ejection fraction (EF): 0.25 ± 0.09 to 0.40 ± 0.11 p<0.001; mean increase 0.15 ± 0.10. Recovery in EF from baseline to 6 mos was related to LVEDD at baseline as shown in the Figure . Kaplan Meier survival n=207 at 1 and 2 years 96% and 94% and transplant free survival at 1 and 2 yrs 92% and 91%. Conclusions: Results of IMAC 2 reveal a marked spontaneous improvement in EF over 6 months, greatest in those with non-dilated LVEDD at baseline, and excellent overall survival in ACM pts treated with evidence based therapies.
Abstract 2968: Postmortem Genetic Testing of the GPD1-L-Encoded Glycerol-3-Phosphate Dehydrogenase 1-Like Protein in Sudden Infant Death Syndrome
Norstrand, David W. Van, Valdivia, Carmen R. , Tester, David J. , Ueda, Kazuo , Makielski, Jonathan C., Ackerman, Michael J. , London, Barry

Mayo Clinic

Circulation | July 3, 2021 | Volume: 116 | Issue: suppl_16 | Pages: No page available

10.1161/circ.116.suppl_16.ii_663-a Get It

Introduction: Approximately 10 – 15% of sudden infant death syndrome (SIDS) may be caused by cardiac channelopathies including Brugada syndrome (BrS). Type 1 BrS (BrS1), due to mutations in the SCN5A-encoded sodium channel, accounts for approximately 20% of BrS. Recently, a novel mutation in glycerol-3-phosphate dehydrogenase 1-like (GPD1-L) disrupted trafficking of SCN5A in a multi-generational family with BrS. We hypothesized that mutations in GPD1-L may be responsible for some cases of SIDS. Methods: Using DHPLC and direct DNA sequencing, we performed comprehensive open reading frame/splice site mutational analysis of GPD1-L on genomic DNA extracted from necropsy tissue of 228 anonymous cases of SIDS (86 females, 142 males, average age = 3 + 2 months, range 6 hours to 12 months). Results: Three putative, SIDS-associated GPD1-L missense mutations, E83K, I124V, and R273C, were discovered in a three-month-old white male, a five-week-old white female, and a one-month-old white male, respectively. All mutations occurred in highly conserved residues and were absent in 600 reference alleles. Compared to wild type GPD1-L, GPD1-L mutations co-expressed with SCN5A in heterologous HEK cells produced a 60% reduction in peak sodium current density (p<0.004). Adenovirus-mediated gene transfer of the E83K-GPD1-L mutation into neonatal mouse myocytes markedly attenuated the sodium current as well (p<0.01). These decreases in current density are consistent with sodium channel loss-of-function diseases like BrS. Conclusion: This study is the first to report mutations in GPD1-L as a pathogenic cause for a small subset (~1%) of SIDS via a secondary loss-of-function mechanism whereby perturbations in GPD1-L precipitate a marked decrease in the peak sodium current and a potentially lethal, BrS-like pro-arrhythmic substrate.
Abstract 2966: Should a Minimum Corrected QT Interval (QTc) be a Prerequisite for Long QT Syndrome Genetic Testing?
Tester, David J. , Carr, Janet L., Harris‐Kerr, Carole, Reed, Carol R. , Ackerman, Michael J. , Salisbury, Benjamin A.

Mayo Clinic

Circulation | July 3, 2021 | Volume: 116 | Issue: suppl_16 | Pages: No page available

10.1161/circ.116.suppl_16.ii_662-b Get It

Background: Long QT Syndrome (LQTS) genetic testing has been available clinically since August 2004. In cases of bona fide LQTS, the yield of genetic testing is approximately 75%. Recently (HRS 2007), Priori and colleagues have suggested that referral for LQTS genetic testing should be based on the screening QTc citing a yield of < 2% for cases referred to their research program with a QTc < 440 ms. Here, we analyze the effect of QTc on the yield in two of the largest assembled cohorts of unrelated patients (pts) referred for LQTS genetic testing. Methods: From August 1997 to July 2006, 1125 unrelated pts (717 females, average age at diagnosis 23.5 yrs, average QTc 473 ms) were referred to either the Mayo Clinic Windland Smith Rice Sudden Death Genomics Laboratory (N = 541) for research-based LQTS genetic testing or to PGxHealth (N = 574) for the FAMILION ® LQTS genetic test. Comprehensive open reading frame and splice site analysis (60 exons) for LQTS-causing mutations involving KCNQ1 (LQT1), KCNH2 (LQT2), SCN5A (LQT3), KCNE1 (LQT5), and KCNE2 (LQT6) was conducted by either dHPLC/DNA sequencing (Mayo), or by direct DNA sequencing (FAMILION). Results: The probability of a positive genetic test increased dramatically with increasing QTc, ranging from 5% for the 38 pts referred for genetic testing despite a QTc < 400 ms to 60% for the 168 pts with a QTc > 500 ms (p < 0.00001). Akin to the Priori cohort, the yield of the genetic test was similar among the subset of pts with a QTc < 470 ms (64% Priori, 61% Mayo cohort, and 53% FAMILION, p = NS). However, the yield for those pts with a QTc between 440 and 470 ms was much greater in the Mayo (49%) and FAMILION (36%) cohorts compared to the Priori cohort (14%, p < 0.0005). In contrast to the 2% yield observed in Italy, 22% of pts with QTc < 440 ms referred to Mayo Clinic and 14.5% of the FAMILION referrals had a positive genetic test (p < 0.001). Conclusions: Whereas only 2% of patients with a QTc < 440 ms had a positive genetic test in Italy, the yield was ten times greater among those referred to Mayo Clinic despite the same QTc cut-off. The cumulative index of suspicion for LQTS rather than a pre-specified QTc cut-off should guide clinical decision making as to the appropriate utilization of the genetic test.
Abstract 2965: Mutations in SNTA1- Encoded Syntrophin α: Characterization of a Novel Long QT Syndrome Susceptibility Gene Involving the Sodium Channel Macromolecular Complex
Valdivia, Carmen R. , Vatta, Matteo , Farrugia, Gianrico , Makielski, Jonathan C., Ackerman, Michael J. , Medeiros‐Domingo, Argelia

Mayo Clinic

Circulation | July 3, 2021 | Volume: 116 | Issue: suppl_16 | Pages: No page available

10.1161/circ.116.suppl_16.ii_662-a Get It

Background: Genes encoding sodium channel interacting proteins (ChIPs) have been identified as novel long QT syndrome (LQTS)-susceptibility genes. Approximately 25% of patients with LQTS remain genotype negative. ChIPs comprising the sodium channel macromolecular complex represent attractive candidates for disease susceptibility. Previously, in human jejunal circular smooth muscle, we demonstrated that syntrophin γ2 regulates sodium channel gating by a PDZ-domain interaction involving the C-terminus. In the heart, syntrophin α is more highly expressed than γ2, therefore, syntrophin α was evaluated as a possible LQTS-susceptibility ChIP. Methods: Comprehensive open reading frame/splice mutational analysis of syntrophin α was performed using PCR, DHPLC, and direct DNA sequencing on a cohort of 50 unrelated patients with LQT1–10 negative/phenotype positive LQTS (34 females; average age at diagnosis 26 ± 16 years; average QTc 531 ± 60.4 ms; QTc range 480 –759 ms). Mutations were engineered by site-directed mutagenesis and transiently expressed in HEK293 cells containing the stably-expressed SCN5A- encoded sodium channel α subunit (hNaV1.5). Results: Analysis of syntrophin α, encoded by SNTA1 , revealed 3 missense mutations in 2 patients (4%). A female diagnosed with LQTS at 13 years (QTc, 480 ms) with family history of autopsy-negative unexplained sudden death, was compound heterozygous for P74L/A257G while a male, diagnosed with LQTS at 18 years following syncopal episodes (QTc, 529 ms), hosted the A390V mutation. These mutations were absent in 600 reference alleles and A257G and A390V involved highly conserved residues. Functional studies revealed a marked leftward shift in sodium current activation for A257G and a significant rightward shift in channel inactivation for A390V-SNTA1. Both kinetic perturbations precipitated a ``gain-of-function” increase in the sodium channel window current. Conclusion: We provide the sentinel report of SNTA1 as a novel LQTS-susceptibility gene with a putative pathogenic mechanism involving a secondary ``gain-of-function” in the NaV1.5 sodium channel. Thus, CAV3-LQTS (LQT9), SCN4B-LQTS (LQT10), and now SNTA1-LQTS represent functional homologues with LQT3-like perturbations.
Abstract 2925: An inherited mutation of AKAP9 (Yotiao) causes Long QT Syndrome (LQTS)
Chen, Lei , Marquardt, Michelle L., Tester, David J. , Sampson, Kevin J. , Ackerman, Michael J. , Kass, Robert S.

Mayo Clinic

Circulation | July 3, 2021 | Volume: 116 | Issue: suppl_16 | Pages: No page available

10.1161/circ.116.suppl_16.ii_653 Get It

A-Kinase Anchoring Protein 9 (AKAP9), or Yotiao, binds to the carboxy-terminus (C-T) of the IKs channel alpha subunit KCNQ1 and recruits cAMP-dependent protein kinase A (PKA) and protein phosphatase 1 (PP1) to the channel to control its phosphorylation state. Previously, an inherited LQT1-causing mutation in the KCNQ1 C-T/Yotiao binding domain was shown to disrupt the complex and render the channel functionally insensitive to cAMP-dependent regulation. Despite the critical role of Yotiao in mediating this fundamental physiological response, the large size of the Yotiao protein (over 200 kD) has hindered patient screens and, to date, no disease-linked mutations have been found in this adaptor protein. The objectives of the present study were first to locate reciprocal binding site(s) for KCNQ1 on Yotiao and to test whether mutation(s) in the binding module(s) might cause LQTS. Using GST fusion protein pull down and immunoprecipitation (IP) techniques, we identified two regions in Yotiao necessary for binding to KCNQ1: one within the Yotiao N-terminus (residues 29 – 46), and a second within its C-terminus (1574 –1643). Targeted sequence analysis was then carried out in fifty clinically diagnosed but genotype negative LQTS patients in the coding regions for these two KCNQ1 binding domains in AKAP9-encoded Yotiao. This analysis identified a novel missense mutation, S1570L-Yotiao, present in two siblings diagnosed with LQTS but absent in the normal population. We found that the S1570L mutation, located close to the Yotiao C-T binding motif for KCNQ1, disrupted the interaction between the two proteins and significantly reduced both basal and exogenous cAMP-induced KCNQ1 phosphorylation. Perforated patch experiments in CHO cells revealed that expression of S1570L-Yotiao significantly reduced basal IKS channel activity and completely ablated the response of the IKs channel to cAMP plus the phosphatase inhibitor okadaic acid. These reconstituted cellular consequences of the inherited S1570L-Yotiao mutation are consistent with delayed repolarization of the ventricular action potential observed in the affected siblings. Thus, we have demonstrated for the first time a link between an inherited AKAP mutation and human disease, LQTS.